首页> 美国卫生研究院文献>Journal of Cancer >BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

【2h】

BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

机译：BCR-ABL1转录物下降率结合BCR-ABL1IS作为慢性粒细胞白血病患者伊马替尼反应和预后的精确预测指标

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Journal of Cancer
作者
Zhimei Cai; Xiting Jia; Jie Zi; Huihui Song; Shujun Wang; Mary McGrath; Lidong Zhao; Chunhua Song; Zheng Ge;
展开▼
作者单位

展开▼
年(卷),期 2020(11),8
年度 2020
页码 -1
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
chronic myeloid leukemia; imatinib; BCR-ABL1; decline;

机译：慢性粒细胞白血病;伊马替尼;BCR-ABL1;下降;

相似文献

外文文献
中文文献
专利

1. BCR-ABL1 transcript decline ratio combined BCR-ABL1 IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia [J] . Zhimei Cai, Xiting Jia, Jie Zi, Journal of Cancer . 2020,第8期

机译：BCR-ABL1转录率下降率组合BCR-ABL1是慢性髓性白血病患者伊马替尼的反应和结果的精确预测因子
2. Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy [J] . Lee Sung-Eun, Choi Soo-Young, Kim Soo-Hyun, Leukemia and lymphoma . 2018,第1a2期

机译：基线BCR-ABL1转录型E13A2和大的脾脏大小是慢性期慢性骨髓性白血病患者在伊马替尼治疗3个月后未能达到早期分子反应的慢性相位慢性骨髓性白血病患者的预测因子
3. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line [J] . Dulucq Stephanie, Etienne Gabriel, Morisset Stephane, Annals of hematology . 2019,第5期

机译：BCR-ABL1成绩单二次下降率对慢性相慢性髓性白血病患者临床结果对伊马替尼第一线的影响
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy [O] . Masayuki Shiseki, Chikashi Yoshida, Naoki Takezako, -1

机译：达沙替尼可快速诱导慢性阶段性髓样白血病患者的深层分子反应这些患者通过伊马替尼治疗可达到可检测水平的BCR-ABL1转录本从而达到主要分子反应
7. BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia [O] . Zhimei Cai, Xiting Jia, Jie Zi, 2020

机译：BCR-ABL1转录比率将BCR-Abl1组合为慢性骨髓白血病患者的伊马替尼反应和结果的精确预测因子

BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

著录项

相似文献

相关主题

期刊订阅